ATMEKSI- methocarbamol suspension

ATMEKSI by

Drug Labeling and Warnings

ATMEKSI by is a Prescription medication manufactured, distributed, or labeled by Metacel Pharmaceuticals, LLC. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Acute, painful musculoskeletal conditions.

    ATMEKSI is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in patients 16 and older.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Important Dosage and Administration Instructions

    Initial dosage: 1,500 mg (10 mL) 4 times daily

    Maintenance dosage: 750 mg (5 mL) every 4 hours or 1,500 mg (10 mL) 3 times daily

    Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.

    Inform the patient to shake the drug product for at least 30 seconds to ensure it is uniform before administration.

  • 3 DOSAGE FORMS AND STRENGTHS

    Oral Suspension: 750 mg/5 mL of methocarbamol as a white to off-white suspension with a fruit flavor

  • 4 CONTRAINDICATIONS

    4.1 Hypersensitivity

    ATMEKSI is contraindicated in patients hypersensitive to methocarbamol or to any of the oral suspension components.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 CNS Depressants and Alcohol Use

    ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol. Patients receiving ATMEKSI (methocarbamol) Oral Suspension should be cautioned about combined effects with alcohol and other CNS depressants [ see Drug Interactions (7.1)].

    5.2 Use in Activities Requiring Mental Alertness

    ATMEKSI may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities.

  • 6 ADVERSE REACTIONS

    The following serious adverse reaction is described elsewhere in the labeling:

    The following adverse reactions associated with the use of methocarbamol have been identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Adverse reactions reported with the administration of methocarbamol include:

    Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache.

    Cardiovascular system:Bradycardia, flushing, hypotension, syncope, thrombophlebitis.

    Digestive system:Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting.

    Hemic and lymphatic system:Leukopenia.

    Immune System:Hypersensitivity reactions.

    Nervous system:Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo.

    Skin and special senses:Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria.

  • 7 DRUG INTERACTIONS

    7.1 CNS drugs and alcohol

    ATMEKSI may potentiate the effects of CNS (central nervous system) depressants and alcohol [ see Warnings and Precautions (5.1)].

    7.2 Pyridostigmine Bromide

    ATMEKSI may inhibit the effect of pyridostigmine bromide. Patients with myasthenia gravis should be monitored closely for symptoms of myasthenia gravis such as weakness. If symptoms of myasthenia gravis are observed, treatment with ATMEKSI should be stopped immediately.

    7.3 Drug/Laboratory Test Interactions

    ATMEKSI may cause color interference in certain screening tests for 5-hydroxyindoleacetic acid (5-HIAA) using nitrosonaphthol reagent and in screening tests for urinary vanillylmandelic acid (VMA) using the Gitlow method.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Limited data from case reports over decades of use with methocarbamol during pregnancy have not identified an increased risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

    The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized patients is 2 to 4% and 15 to 20% respectively.

    8.2 Lactation

    Risk Summary

    There are no data on the presence of methocarbamol or its metabolites in human milk, the effects on a breastfed infant or the effects on milk production. Methocarbamol and/or its metabolite are present in animal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ATMEKSI and any potential adverse effects on the breastfed infant from ATMEKSI or the underlying maternal condition.

    8.4 Pediatric Use

    Safety and effectiveness of methocarbamol oral suspension in pediatric patients below the age of 16 have not been established.

  • 10 OVERDOSAGE

    Clinical Presentation

    Deaths have been reported with an overdose of methocarbamol alone and when methocarbamol was used with other CNS depressants, including alcohol. Limited information is available on the acute toxicity of methocarbamol. Symptoms of overdose include the following: respiratory depression, nausea, drowsiness, blurred vision, hypotension, seizures, coma, and death. Other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants) can have an additive effect, even when taken at recommended dosages.

    Treatment of Overdose

    The standard of treatment is supportive care, including monitoring for CNS and respiratory depression and managing airway as needed, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary.

    Hypotension should be treated with intravenous fluids and vasopressors as needed. Gastrointestinal decontamination procedures (including emesis) should generally be avoided because aspiration may result from CNS depression and seizures. Extracorporeal elimination such as hemodialysis or plasmapheresis has no proven clinical benefit. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

  • 11 DESCRIPTION

    ATMEKSI (methocarbamol) Oral Suspension is a central nervous system (CNS) depressant with sedative and musculoskeletal relaxant properties.

    The chemical name of methocarbamol is (±)1,2-Propanediol, 3-(2-methoxyphenoxy)-, 1-carbamate, or (±)-3-(o-Methoxyphenoxy)-1,2-propanediol 1-carbamate and has the empirical formula C11H15NO5. Its molecular weight is 241.24g/mol. The structural formula is shown below:

    formula

    Methocarbamol is a white powder, sparingly soluble in water and in chloroform, soluble in alcohol (only with heating), insoluble in benzene and in n-hexane.

    ATMEKSI (methocarbamol) Oral Suspension is a white to off-white suspension with a fruit flavor and a pH range of 3.2 – 4.8.

    ATMEKSI (methocarbamol) Oral Suspension contains the following inactive ingredients: citric acid monohydrate, glycerin, magnesium aluminum silicate, purified water, sodium benzoate, sodium carboxymethylcellulose, sodium citrate, sucralose and fruit flavor.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of action of methocarbamol in humans has not been established but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber.

    12.3 Pharmacokinetics

    Absorption

    After oral administration in healthy volunteers, ATMEKSI is rapidly absorbed with a median Tmax of 0.66 hours. Food decreases the extent and delays the rate of absorption of methocarbamol. In the presence of food, the Cmax is decreased by 51% and the AUC is decreased by 31%. The median Tmax is delayed to 1.6 hours.

    Distribution

    Methocarbamol demonstrates moderate binding to plasma proteins, typically ranging from 46% to 50%.

    Elimination

    In healthy volunteers, the plasma clearance of methocarbamol ranges between 0.20 and 0.80 L/h/kg. The mean plasma elimination half-life of ATMEKSI in healthy volunteers is approximately 1.3 hours and 1.5 hours when administered with or without food.

    Metabolism

    Methocarbamol is metabolized via dealkylation and hydroxylation. Conjugation of methocarbamol also is likely. Essentially all methocarbamol metabolites are eliminated in the urine.

    Excretion

    Small amounts of unchanged methocarbamol also are excreted in the urine.

    Specific Populations

    Geriatric Patients

    The mean (± SD) elimination half-life of methocarbamol in elderly healthy volunteers (mean (± SD) age, 69 (± 4) years) was slightly prolonged compared to a younger (mean (± SD) age, 53.3 (± 8.8) years), healthy population (1.5 (± 0.4) hours versus 1.1 (± 0.27) hours, respectively). The fraction of bound methocarbamol was slightly decreased in the elderly versus younger volunteers (41 to 43% versus 46 to 50%, respectively).

    Pediatric Patients

    Safety and effectiveness of methocarbamol oral suspension in pediatric patients below the age of 16 have not been established.

    Patients with Renal Impairment

    The clearance of methocarbamol in 8 renally-impaired patients on maintenance hemodialysis was reduced about 40% compared to 17 normal subjects, although the mean (± SD) elimination half-life in these two groups was similar: 1.2 (± 0.6) versus 1.1 (± 0.3) hours, respectively.

    Patients with Hepatic Impairment

    In 8 patients with cirrhosis secondary to alcohol abuse, the mean total clearance of methocarbamol was reduced approximately 70% compared to that obtained in 8 age- and weight-matched normal subjects. The mean (± SD) elimination half-life in the cirrhotic patients and the normal subjects was 3.38 (± 1.62) hours and 1.11 (± 0.27) hours, respectively. The percent of methocarbamol bound to plasma proteins was decreased to approximately 40 to 45% compared to 46 to 50% in the normal subjects.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Long-term studies to evaluate the carcinogenic potential of methocarbamol have not been performed.

    Mutagenesis

    No studies have been conducted to assess the effect of methocarbamol on mutagenesis.

    Impairment of Fertility

    No studies have been conducted to assess the effect of methocarbamol on its potential to impair fertility.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    16.1 How Supplied

    ATMEKSI (methocarbamol) Oral Suspension contains 750 mg/5 mL methocarbamol. It is a white to off-white suspension with a fruit flavor and is supplied in bottles of 150 mL with a child-resistant closure (NDC: 69528-701-05).

    16.2 Storage and Handling

    Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Keep out of reach and sight of children.

  • 17 PATIENT COUNSELING INFORMATION

    • Caution patients that ATMEKSI may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery.
    • Because ATMEKSI may possess a general CNS-depressant effect, caution patients about combined effects with alcohol and other CNS depressants.
  • SPL UNCLASSIFIED SECTION

    Manufactured for:

    Rosemont Pharmaceuticals, LLC

    Greenville, SC 29615

    www.rosemontpharmaceuticals.com

    ATMEKSI ®is a registered trademark of Rosemont Pharmaceuticals Ltd.

    PI-MET-01-001

  • Principal Display Panel - 150 mL Bottle

    NDC: 69528-701-05

    Atmeksi

    (methocarbamol)

    Oral Suspension

    750 mg/5 mL

    150 mL

    atmeksi bottle

  • INGREDIENTS AND APPEARANCE
    ATMEKSI 
    methocarbamol suspension
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 69528-701
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    METHOCARBAMOL (UNII: 125OD7737X) (METHOCARBAMOL - UNII:125OD7737X) METHOCARBAMOL750 mg  in 5 mL
    Inactive Ingredients
    Ingredient NameStrength
    CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)  
    SODIUM CITRATE (UNII: 1Q73Q2JULR)  
    MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC)  
    SODIUM BENZOATE (UNII: OJ245FE5EU)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    SUCRALOSE (UNII: 96K6UQ3ZD4)  
    CARBOXYMETHYLCELLULOSE SODIUM (UNII: K679OBS311)  
    WATER (UNII: 059QF0KO0R)  
    Product Characteristics
    Color    Score    
    ShapeSize
    FlavorFRUITImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 69528-701-05150 mL in 1 BOTTLE; Type 0: Not a Combination Product01/15/2026
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21984312/22/2025
    Labeler - Metacel Pharmaceuticals, LLC (079475312)

    • Trademark Results [ATMEKSI]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    ATMEKSI
    ATMEKSI
    98200219 not registered Live/Pending
    Rosemont Pharmaceuticals Limited
    2023-09-27
    © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.